effect overlay
activetrials
Active Trials - Other
Huntington's Disease
Skyhawk HD Phase 2

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

HREC: 2025.141
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Anice Abin & Lei Chen
Funding: Commercial
Active Trials - Other
Neurophysiology
EMPASSION

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

HREC: 2025.002
Principal Investigator: Dr Belinda Cruse
Coordinator contact: Kate Furlong
Funding: Commercial
Active Trials - Other
Huntington's Disease
Skyhawk HD

A Phase I Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect of Food on the Bioavailability of SKY-0515 in Healthy Volunteers and Patients with Huntington’s Disease

HREC: 2024.165
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Anice Abin & Lei Chen
Funding: Commercial
Active Trials - Other
Peripheral Neuropathy
Argenx BV

A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy (MMN)

HREC: 2024.051
Principal Investigator: Dr Belinda Cruse
Coordinator contact: Callum Hollis
Funding: Commercial
Active Trials - Other
Neurophysiology
Myasthenia Gravis Health Economic Modelling

An investigator-initiated national prospective health economics study to optimise the use of immunoglobulin treatment in adults with Myasthenia Gravis

HREC: 2024.022
Principal Investigator: Dr Belinda Cruse
Coordinator contact:
Funding: Non-Commercial